The FY2026 20-F confirms the TACTI-004 failure and a worsening financial profile. The root cause analysis is ongoing, and the company is pivoting to HNSCC (CPS<1) and STS. Monitor for the root cause analysis update and any potential partnership or financing events. The ADS ratio change resolved the Nasdaq bid price deficiency, but the stock remains a high-risk, pre-revenue biotech with a single late-stage asset.
Price Chart
Executive Summary
Immutep's FY2026 20-F annual report confirms the devastating impact of the TACTI-004 Phase III trial discontinuation in March 2026. The company reported a net loss of A$79.3 million, a 29% increase from A$61.4 million in FY2025, driven by a A$3.1 million impairment on efti-related IP and elevated clinical trial close-out costs. Cash and cash equivalents and term deposits total A$68.9 million, providing runway into H1 CY2028, but the lead pipeline program is effectively stalled pending root cause analysis, and the stock closed at A$0.05 (down from A$0.24 a year earlier).
Key Facts
- Net loss for FY2026: A$79.3 million vs A$61.4 million in FY2025
- License revenue from Dr. Reddys: A$14.6 million (US$10 million recognized); US$10 million repaid after TACTI-004 discontinuation
- Cash & cash equivalents + term deposits: A$68.9 million (A$63.7M cash + A$5.2M term deposits)
- R&D and IP expenses: A$91.9 million, up from A$61.4 million YoY
- Impairment on efti-related IP: A$3.1 million non-cash charge
- TACTI-004 Phase III trial discontinued after interim futility analysis
- Root cause analysis identified subtle structural differences between 2000L and 200L scale efti
- Nasdaq minimum bid price compliance regained via ADS ratio change effective Sept 28, 2026
- Headcount reduction and cost-cutting initiatives implemented post-TACTI-004
- No convertible notes remain outstanding as of June 30, 2026
Financial Impact
Net loss of A$79.3 million for FY2026, up 29% from A$61.4 million in FY2025. R&D expenses increased to A$91.9 million, driven by TACTI-004 close-out costs and a A$3.1 million impairment charge on efti-related IP. Cash runway into H1 CY2028.
Risk Factors
- Root cause analysis may not identify the cause of TACTI-004 failure, delaying efti's future development
- Cash runway into H1 CY2028 may be insufficient without additional financing or partnership
- Potential delisting risk if Nasdaq minimum bid price compliance is not maintained
- Reliance on WuXi Biologics for efti manufacturing, subject to BIOSECURE Act risks
- No approved products or material revenue from product sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001193125-26-429413 |
| Document: d109552dex416.htm | 0001193125-26-429413 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 20-F | $3.17 | awaiting T+5 | — | $3.20 (−0.95%) |
Oct 13, 2026 12d ago | 6-K | $3.38 $3.28 | ▼ −2.96% | ▼ −3.41% | $3.20 (−5.33%) |
Sep 22, 2026 4w ago | 6-K | $0.2800 | awaiting T+5 | — | $3.20 (+1042.86%) |
Sep 1, 2026 7w ago | 6-K | $0.3800 $0.3300 | ▲ +13.16% | ▲ +12.20% | $3.20 (−742.11%) |
Jul 13, 2026 14w ago | 6-K | $0.4328 $0.3993 | ▼ −7.74% | ▼ −7.27% | $3.20 (+639.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers